Glasgow, UK, Thursday 30 November 2017 07.25 GMT
A new study confirms that deprexis® reduces total health insurance costs. GAIA’s leading digital therapy software is proven to facilitate reliable reduction of symptoms.
These findings were presented at the annual European Congress of ISPOR (the International Society for Pharmacoeconomics and Outcomes Research). The results have also been published in Value in Health (2017), a journal of original research on health economics.
A total of 3,806 participants were randomized into one of two groups, making this one of the largest trials ever in this field. All participants were recruited from a major German statutory health insurance (DAK Gesundheit).
For 12-weeks, the intervention group was treated with deprexis® while those in the control group received depression related online information plus usual care. Compared to control group participants, those in the intervention group experienced significantly greater depression reductions. They also experienced improvements in quality of life and a drop in total costs of statutory health insurance.
These results demonstrate that GAIA´s digital software solutions are both cost and clinically effective. We regard this as an important mandate in our quest to improve the quality of health care without increasing costs.
The report is available at http://dx.doi.org/10.1016/j.jval.2017.08.1893